FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183082503> ?p ?o ?g. }

• W2183082503 abstract "Background: Plerixafor is a CXCR4 receptor inhibitor, which was recently introduced for stem cell mobilization in myeloma and lymphoma patients prior to their transplantation. Since March 2009, we performed 16 mobilizations using plerixafor in combination with G-CSF in 10 patients with multiple myeloma, 3 Non-Hodgkin’s lymphoma and 3 Hodgkin’s lymphoma, who failed previous mobilization attempts with G-CSF in combination with chemotherapy.Methods and Findings: Our protocol consisted of daily s.c. injections of G-CSF (2 x 5 µg/kg) on days 1 through 7 and plerixafor (240 µg/kg) on day 4, 5 and 6. In three patients, plerixafor was added to chemotherapy-based mobilization regimen, in case when No. of CD34+ cell was too low to start cell collections. The median No. of circulating CD34+ cells after first administration of plerixafor was 23/µL (range 11-62) and in 13/16 patients it exceeded minimum of 15 cells/µL required to begin leukapheresis on that day. However, due to high peripheral blood leukocytosis (median 36.5 G/L; range, 11.4-72.5) the frequency of CD34+ cells was low (median 0.067%, range 0.030-0.215) that affected low collection efficiency of CD34+ cells. Moreover, this required collection and freezing of abundant No. of nucleated cells (median 9.3 x 108 NCs/kg, range 6.15-24.05). In our setting, high nucleated cell count translated into high volume of stem cell product (median 1260 mL; range 500-2050). Nevertheless, the final stem cell products contained median of 2.8 x 106 CD34+ cells/kg b.w. (range, 0.57-4.5 x 106) and in 12/16 patients (75%) it exceeded 2.0 x 106 CD34+ cells/kg b.w., which is required for stem cell transplantation. Eight patients have already been transplanted and median time to neutrophil (>0.5 G/L) recovery was 12 days (11-14) and platelet (>20 G/L) recovery was 14 days (10-25) that is satisfactory.Conclusions: Stem cell mobilization with plerixafor and G-CSF provides solution for majority of patients requiring autologous hematopoietic stem cell transplantation and failing mobilization with G-CSF in combination with chemotherapy. However, due to high leukocytosis, this protocol requires modification of stem cell collection and freezing procedures in order to avoid large volumes of stem cell product." @default.
• W2183082503 created "2016-06-24" @default.
• W2183082503 creator A5003517613 @default.
• W2183082503 creator A5009020123 @default.
• W2183082503 creator A5011778759 @default.
• W2183082503 creator A5018780908 @default.
• W2183082503 creator A5024817918 @default.
• W2183082503 creator A5031283927 @default.
• W2183082503 creator A5037604598 @default.
• W2183082503 creator A5039383883 @default.
• W2183082503 creator A5041440288 @default.
• W2183082503 creator A5046381896 @default.
• W2183082503 creator A5051673407 @default.
• W2183082503 creator A5056073840 @default.
• W2183082503 creator A5061299820 @default.
• W2183082503 creator A5061970552 @default.
• W2183082503 creator A5066581236 @default.
• W2183082503 creator A5075090733 @default.
• W2183082503 creator A5084110989 @default.
• W2183082503 date "2010-01-01" @default.
• W2183082503 modified "2023-09-23" @default.
• W2183082503 title "CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt" @default.
• W2183082503 cites W1978321902 @default.
• W2183082503 cites W1982986673 @default.
• W2183082503 cites W1994809546 @default.
• W2183082503 cites W2019381460 @default.
• W2183082503 cites W2020806642 @default.
• W2183082503 cites W2023512317 @default.
• W2183082503 cites W2030846042 @default.
• W2183082503 cites W2047025080 @default.
• W2183082503 cites W2049859652 @default.
• W2183082503 cites W2056550360 @default.
• W2183082503 cites W2085269642 @default.
• W2183082503 cites W2088730492 @default.
• W2183082503 hasPublicationYear "2010" @default.
• W2183082503 type Work @default.
• W2183082503 sameAs 2183082503 @default.
• W2183082503 citedByCount "2" @default.
• W2183082503 countsByYear W21830825032012 @default.
• W2183082503 crossrefType "journal-article" @default.
• W2183082503 hasAuthorship W2183082503A5003517613 @default.
• W2183082503 hasAuthorship W2183082503A5009020123 @default.
• W2183082503 hasAuthorship W2183082503A5011778759 @default.
• W2183082503 hasAuthorship W2183082503A5018780908 @default.
• W2183082503 hasAuthorship W2183082503A5024817918 @default.
• W2183082503 hasAuthorship W2183082503A5031283927 @default.
• W2183082503 hasAuthorship W2183082503A5037604598 @default.
• W2183082503 hasAuthorship W2183082503A5039383883 @default.
• W2183082503 hasAuthorship W2183082503A5041440288 @default.
• W2183082503 hasAuthorship W2183082503A5046381896 @default.
• W2183082503 hasAuthorship W2183082503A5051673407 @default.
• W2183082503 hasAuthorship W2183082503A5056073840 @default.
• W2183082503 hasAuthorship W2183082503A5061299820 @default.
• W2183082503 hasAuthorship W2183082503A5061970552 @default.
• W2183082503 hasAuthorship W2183082503A5066581236 @default.
• W2183082503 hasAuthorship W2183082503A5075090733 @default.
• W2183082503 hasAuthorship W2183082503A5084110989 @default.
• W2183082503 hasConcept C10205521 @default.
• W2183082503 hasConcept C126322002 @default.
• W2183082503 hasConcept C129470790 @default.
• W2183082503 hasConcept C13373296 @default.
• W2183082503 hasConcept C141071460 @default.
• W2183082503 hasConcept C143998085 @default.
• W2183082503 hasConcept C170493617 @default.
• W2183082503 hasConcept C2776364478 @default.
• W2183082503 hasConcept C2776694085 @default.
• W2183082503 hasConcept C2777371436 @default.
• W2183082503 hasConcept C2777767877 @default.
• W2183082503 hasConcept C2778828106 @default.
• W2183082503 hasConcept C2779050716 @default.
• W2183082503 hasConcept C2779338263 @default.
• W2183082503 hasConcept C2781413609 @default.
• W2183082503 hasConcept C28328180 @default.
• W2183082503 hasConcept C54355233 @default.
• W2183082503 hasConcept C71924100 @default.
• W2183082503 hasConcept C86803240 @default.
• W2183082503 hasConceptScore W2183082503C10205521 @default.
• W2183082503 hasConceptScore W2183082503C126322002 @default.
• W2183082503 hasConceptScore W2183082503C129470790 @default.
• W2183082503 hasConceptScore W2183082503C13373296 @default.
• W2183082503 hasConceptScore W2183082503C141071460 @default.
• W2183082503 hasConceptScore W2183082503C143998085 @default.
• W2183082503 hasConceptScore W2183082503C170493617 @default.
• W2183082503 hasConceptScore W2183082503C2776364478 @default.
• W2183082503 hasConceptScore W2183082503C2776694085 @default.
• W2183082503 hasConceptScore W2183082503C2777371436 @default.
• W2183082503 hasConceptScore W2183082503C2777767877 @default.
• W2183082503 hasConceptScore W2183082503C2778828106 @default.
• W2183082503 hasConceptScore W2183082503C2779050716 @default.
• W2183082503 hasConceptScore W2183082503C2779338263 @default.
• W2183082503 hasConceptScore W2183082503C2781413609 @default.
• W2183082503 hasConceptScore W2183082503C28328180 @default.
• W2183082503 hasConceptScore W2183082503C54355233 @default.
• W2183082503 hasConceptScore W2183082503C71924100 @default.
• W2183082503 hasConceptScore W2183082503C86803240 @default.
• W2183082503 hasIssue "1" @default.
• W2183082503 hasLocation W21830825031 @default.
• W2183082503 hasOpenAccess W2183082503 @default.
• W2183082503 hasPrimaryLocation W21830825031 @default.
• W2183082503 hasRelatedWork W1495708481 @default.

• next